Brooklyn Investment Group reduced its holdings in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 34.8% during the 4th quarter, ...

Research analysts at Leerink Partnrs issued their Q4 2025 earnings estimates for Moderna in a research note issued to ...

Human metapneumovirus (HMPV) is a commonly found virus that can cause respiratory illness. Although it typically has no symptoms in healthy people, it can cause serious sickness in older adults, those ...

Moderna advances combo vaccine for flu and COVID-19 with trials starting in March Pharmaceutical companies gear up to tackle rising respiratory virus threats with innovative vaccine development.

Not many people had heard of human metapneumovirus, or HPMV, until a surge of recent cases in China made headlines.

Five years after the first cases of COVID-19, reports of hMPV, an obscure respiratory virus in China may understandably raise ...

Analysis - Five years on from the first news of Covid-19, recent reports of an obscure respiratory virus in China may ...

The Centers for Disease Control and Prevention is currently monitoring reports of a spike in human metapneumovirus (HMPV) in China, as the US sees an increase in such cases. The CDC said it was aware ...

Most children have had HMPV by the time they reach the age of ... There’s currently no cure or vaccine for the disease, though Moderna, the maker of a COVID-19 vaccine, is working to produce ...

Last summer, scientists at the University of Oxford launched a clinical trial of a combined RSV and hMPV vaccine in partnership with Moderna, and Andrew Pollard, a professor of infection and ...

This has led to the hope that similar products may be developed for hMPV, and Moderna has recently started trials into a mRNA hMPV vaccine. There are no treatments that have been clearly ...